A phase III trial showed that people with previously untreated BRAF V600 mutation-positive advanced melanoma who received the MEK inhibitor cobimetinib plus Zelboraf (vemurafenib) lived significantly longer without their disease worsening or death compared to Zelboraf alone.
Phase III data from the LUX-Lung 8 head-to-head trial, evaluating Gilotrif versus erlotinib in patients with advanced squamous cell carcinoma of the lung, demonstrated superior improvement in progression-free survival with Gilotrif.
A STAND UP TO CANCER inaugural Dream Team launched in 2009 to focus on epigenetic therapy will continue with a commitment of $7.5 million from the Van Andel Research Institute.
THE ASSOCIATION OF COMMUNITY CANCER CENTERS received a charitable contribution from Bristol-Myers Squibb to develop a comprehensive program in immuno-oncology for community-based providers.
NORTHWESTERN MUTUAL, through its foundation, will fund four young investigator grants for childhood cancer research. The awards support Alex’s Lemonade Stand Foundation’s young investigator program. The addition of these four research projects results in eight total funded research projects this year, an $800,000 commitment. Each researcher receives a total grant of $100,000 over two-years. Four […]
MARY KOZIK was named senior director of development at Winship Cancer Institute of Emory University.
JAMES TULSKY received the Pathfinder in Palliative Care Award from the American Cancer Society.
DAVID MAURO was named as executive vice president and chief medical officer of Advaxis Inc.
RICHARD ZELLARS was named professor and chair of radiation oncology at the Indiana University School of Medicine, pending approval by the IU trustees. He will begin his new duties in January.
BENJAMIN NEEL was named director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center. He will begin Jan. 1, 2015.
